<SEC-DOCUMENT>0001193125-25-257347.txt : 20251030
<SEC-HEADER>0001193125-25-257347.hdr.sgml : 20251030
<ACCEPTANCE-DATETIME>20251030063705
ACCESSION NUMBER:		0001193125-25-257347
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20251030
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251030
DATE AS OF CHANGE:		20251030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvalent, Inc.
		CENTRAL INDEX KEY:			0001861560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40671
		FILM NUMBER:		251432076

	BUSINESS ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		508-446-2272

	MAIL ADDRESS:	
		STREET 1:		ONE BROADWAY, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nuvl-20251030.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-10-29T10:55:13.4557+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nuvl="http://www.nuvalent.com/20251030" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_89f59280-d8f3-447d-aff8-b9d365882a8c" name="dei:AmendmentFlag" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_7054fb88-614d-46cc-915f-65eee7d64132" name="dei:EntityCentralIndexKey" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e">0001861560</ix:nonNumeric><ix:nonNumeric id="F_88a899f4-0f6b-41ac-8118-7367fb65b1b8" name="dei:DocumentPeriodEndDate" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" format="ixt:date-monthname-day-year-en">October 30, 2025</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nuvl-20251030.xsd"/></ix:references><ix:resources><xbrli:context id="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001861560</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-30</xbrli:startDate><xbrli:endDate>2025-10-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1.5pt double #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:40.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;margin-right:40.741%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50d5accb-cfa2-4abd-b085-2bc11da5c74d" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p><p style="margin-left:40.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;margin-right:40.741%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Securities Exchange Act of 1934</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): October 30</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_88a899f4-0f6b-41ac-8118-7367fb65b1b8;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2025</span></span></span></p><p style="margin-left:40.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;margin-right:40.741%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5453cb9d-6e87-48a3-8518-38b7f9807562" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUVALENT, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p><p style="margin-left:40.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;margin-right:40.741%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e4cd871f-ca29-4943-bbbd-ee458fd8514f" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ce06a6cc-93db-44c8-8da6-c3316d2c236e" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-40671</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2e033c45-9294-44a1-9d72-c7a1f4020f6e" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81-5112298</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction<br/>of incorporation)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission<br/>File Number)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39e25be9-cbee-4363-99e3-7b8c1929f463" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One Broadway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76eb890e-a6fe-4b05-b086-48ab1fa2e4a7" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14th Floor</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f850d876-dbc2-44a5-8af7-e02374202274" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2371a8b9-05f7-4687-9021-fb7ffd7f008e" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3f6fcc3-f966-4219-a45f-fd0045f6e4a4" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">02142</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27c963e0-23e5-40a9-bcfa-3d6b24e6a173" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(857)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9710ec7-d4f6-4872-8b54-3684d7a14ad1" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">357-7000</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40.747%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;margin-right:40.741%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_3ea54912-5906-4e82-bfb7-5ec75f26b856" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_5a64d1a3-eaa6-464c-bb0c-3b9a04198e27" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_721632af-2e9b-450f-97a9-5a9bfab7f94f" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a28366c5-0772-4de5-b30f-1f95b89c9c0e" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:19.22%;box-sizing:content-box;"/>
     <td style="width:2.22%;box-sizing:content-box;"/>
     <td style="width:35.56%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trade<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange<br/>on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8761d797-43d2-4f0b-b077-1623f7adc249" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1e7ba9cc-8448-4529-a456-14672eb67a52" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">NUVL</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d9fb62fd-7516-45c0-bd3c-9b8073fa581c" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b50ef5bc-8486-44b2-8cd5-38fbbde9086f" contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1.5pt double #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02. Results of Operations and Financial Condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 30, 2025, Nuvalent, Inc. announced its financial results for the quarter ended September 30, 2025, and other corporate updates. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01. Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.72%;box-sizing:content-box;"/>
     <td style="width:1.38%;box-sizing:content-box;"/>
     <td style="width:87.9%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="nuvl-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by Nuvalent, Inc. on October 30, 2025</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nuvalent, Inc.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 30, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James R. Porter, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James R. Porter, Ph.D.<br/>President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nuvl-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-10-29T10:55:13.4772+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><img src="img8926856_0.jpg" alt="img8926856_0.jpg" style="width:162px;height:40px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7.2pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC by year-end 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strong financial position with operating runway anticipated into 2028</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAMBRIDGE, Mass. &#x2014; October 30, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x2014; </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">precisely</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and reported third quarter 2025 financial results.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;The third quarter of 2025 marked the achievement of a significant milestone with the completion of our NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC. We look forward to working closely with the FDA throughout the review process, as well as continuing to engage with the agency on potential opportunities for line-agnostic expansion,&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">said Darlene Noci, A.L.M., Chief Development Officer of Nuvalent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. &#x201c;We remain on track to share topline pivotal data this quarter from our ALKOVE-1 trial of neladalkib in TKI pre-treated advanced ALK-positive NSCLC, and continue to progress ALKAZAR, our global Phase 3 randomized, controlled trial of neladalkib for TKI-na&iuml;ve patients with advanced ALK-positive NSCLC.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Our commercial preparedness activities are well underway as we carry forward the momentum from these exciting development milestones and continue our efforts to transition toward becoming a fully integrated commercial-stage biopharmaceutical company,&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> said Alex Balcom, Chief Financial Officer of Nuvalent. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Combined with a strong financial position with cash runway anticipated into 2028, we believe we are well positioned to achieve our goal of delivering a new and potential best-in-class option for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">all </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients with ROS1 or ALK-positive NSCLC.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;We are also pleased to have recently shared the first report of preliminary clinical data demonstrating the potential for neladalkib to address medical needs for patients with ALK-positive solid tumors beyond NSCLC, and new preclinical data further demonstrating the potential for NVL-330 to offer a differentiated profile for HER2-altered NSCLC,&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">said James Porter, Ph.D., Chief Executive Officer of Nuvalent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. &#x201c;With a portfolio anchored by complementary indications in biomarker-driven NSCLC and supported by a robust development and discovery pipeline, we continue to build towards our long-term vision of Nuvalent as a sustainable company capable of designing, developing and delivering </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">precisely </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">targeted therapies for patients with cancer.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Pipeline Achievements and Anticipated Milestones</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ROS1 Program</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company has completed its rolling NDA submission for zidesamtinib in tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><img src="img8926856_0.jpg" alt="img8926856_0.jpg" style="width:162px;height:40px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data supporting the NDA submission were presented in September as part of the Presidential Symposium at the IASLC 2025 World Conference on Lung Cancer.</font></div></div><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company continues to engage with the FDA on potential opportunities for line-agnostic expansion.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALK Program</font></p><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of neladalkib is ongoing in the ALKOVE-1 Phase 1/2 trial for patients with advanced ALK-positive NSCLC and other solid tumors:</font></div></div><div class="item-list-element-wrapper" style="margin-left:8%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.8989130434782604%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company presented preliminary data from the ongoing ALKOVE-1 Phase 1/2 clinical trial of neladalkib in patients with advanced ALK-positive solid tumors outside of NSCLC during a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025.</font><font style="color:#ee0000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neladalkib demonstrated encouraging preliminary activity across a diverse set of advanced ALK-positive solid tumors, and was generally well-tolerated with a preliminary overall safety profile consistent with its ALK-selective, TRK sparing design, and with previously reported data.</font></div></div><div class="item-list-element-wrapper" style="margin-left:8%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.8989130434782604%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company is on track to report topline pivotal data for TKI pre-treated patients with advanced ALK-positive NSCLC by year-end 2025.</font></div></div><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment is ongoing in ALKAZAR, the company's global Phase 3 randomized, controlled trial designed to evaluate neladalkib for the treatment of patients with TKI-na&iuml;ve ALK-positive NSCLC. Patients are randomized 1:1 to receive neladalkib or alectinib, a front-line standard of care, reflecting input from collaborating physician-scientists and alignment with global regulatory agencies. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HER2 Program</font></p><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent presented new preclinical data for its novel HER2-selective inhibitor, NVL-330, at the AACR-NCI-EORTC</font><font style="color:#ee0000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International Conference on Molecular Targets and Cancer Therapeutics, further supporting its potentially differentiated brain-penetrant profile. Compared to several currently available and investigational HER2 TKIs in the same preclinical assays, NVL-330 demonstrated a favorable efflux ratio and brain partitioning, metrics that are potentially positive predictors of brain exposure in humans. In preclinical models of intracranial activity, NVL-330 induced deep intracranial regression in mice. In the same models, the approved therapies T-DXd and zongertinib did not induce intracranial regression at their clinically relevant doses. Additionally, NVL-330 induced intracranial tumor regression in mice that had progressed in the CNS on zongertinib. These data add to the preclinical characterization of NVL-330 as a brain penetrant TKI that is broadly active against HER2 oncogenic alterations and selective over wild-type EGFR, and the company believes the data support its investigation in patients with advanced HER2-altered NSCLC.</font></div></div><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enrollment is ongoing in the HEROEX-1 Phase 1a/1b clinical trial evaluating the overall safety and tolerability of NVL-330 for pre-treated patients with HER2-altered NSCLC. Additional objectives include determination of the recommended Phase 2 dose, characterization of NVL-330's pharmacokinetic profile, and preliminary evaluation of anti-tumor activity. The company expects to continue to progress the HEROEX-1 trial throughout 2025.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upcoming Events</font></p><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jefferies 2025 Global Healthcare Conference in London:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Management will be participating in a fireside chat on Wednesday, November 19, 2025, at 5:00 p.m. GMT. A live webcast will be </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><img src="img8926856_0.jpg" alt="img8926856_0.jpg" style="width:162px;height:40px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available in the Investors section of Nuvalent's website at </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.nuvalent.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and will be archived for 30 days following the conference.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Quarter 2025 Financial Results</font></p><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Position:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cash, cash equivalents and marketable securities were $943.1 million as of September 30, 2025. Nuvalent continues to believe its existing cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan into 2028.</font></div></div><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Research and development (R&amp;D) expenses were $83.8 million for the third quarter of 2025.</font></div></div><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G&amp;A Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> General and administrative (G&amp;A) expenses were $28.9 million for the third quarter of 2025.</font></div></div><div class="item-list-element-wrapper" style="margin-left:2.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.7400778769790306%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Net loss was $122.4 million for the third quarter of 2025.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Nuvalent</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">precisely</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the period over which Nuvalent estimates its cash, cash equivalents and marketable securities will be sufficient to fund its future operating expenses and capital expenditure requirements; the expected timing of data announcements, clinical trial initiations and FDA product approvals, including potential line-agnostic approvals; the preclinical and clinical development programs for zidesamtinib, neladalkib and NVL-330; the potential benefits and effects of Nuvalent&#x2019;s product development candidates; the design and enrollment of its clinical trials; the potential of Nuvalent's pipeline programs, including zidesamtinib, neladalkib and NVL-330; the implications of data readouts and presentations; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;aim,&#34; &#34;goal,&#34; &#34;intend,&#34; &#34;believe,&#34; &#34;estimate,&#34; &#34;seek,&#34; &#34;predict,&#34; &#34;future,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;target&#34; or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll its</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><img src="img8926856_0.jpg" alt="img8926856_0.jpg" style="width:162px;height:40px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies or clinical trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from our clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of our product candidates; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled &#34;Risk Factors&#34; in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Contact</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chelcie Lister</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nuvalent, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clister@nuvalent.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Media Contact</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Josie Butler<br>1AB</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">josie@labmedia.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><img src="img8926856_0.jpg" alt="img8926856_0.jpg" style="width:162px;height:40px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:1.204%;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:42.509%;box-sizing:content-box;"></td>
     <td style="width:13.203%;box-sizing:content-box;"></td>
     <td style="width:1.58%;box-sizing:content-box;"></td>
     <td style="width:13.123%;box-sizing:content-box;"></td>
     <td style="width:1.58%;box-sizing:content-box;"></td>
     <td style="width:13.203%;box-sizing:content-box;"></td>
     <td style="width:1.58%;box-sizing:content-box;"></td>
     <td style="width:13.223%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.1pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="8" style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></p></td>
    </tr>
    <tr style="height:12.1pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="8" style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.1pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="8" style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
    </tr>
    <tr style="height:12.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended September 30,</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nine Months Ended September 30,</font></p></td>
    </tr>
    <tr style="height:12.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                   83,843</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                   60,551</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                 239,174</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                 148,351</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28,853</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,780</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;72,905</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;45,718</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;112,696</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;76,331</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;312,079</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;194,069</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(112,696)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(76,331)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(312,079)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(194,069)</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of related party revenue share liability</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(19,810)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(16,600)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(27,280)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(16,600)</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income and other income (expense), net</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;10,201</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,626</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,121</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25,269</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income (expense), net</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,609)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(7,974)</font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,841</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8,669</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(122,305)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(84,305)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(306,238)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(185,400)</font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;132</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;40</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;434</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;593</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$               (122,437)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                 (84,345)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$               (306,672)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$               (185,993)</font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                     (1.70)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                     (1.28)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                     (4.27)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$                     (2.87)</font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average shares of common stock outstanding, basic and diluted</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;72,143,466</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;65,678,693</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;71,866,892</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;64,814,695</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><img src="img8926856_0.jpg" alt="img8926856_0.jpg" style="width:162px;height:40px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:1.204%;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:46.939%;box-sizing:content-box;"></td>
     <td style="width:25.061%;box-sizing:content-box;"></td>
     <td style="width:2.041%;box-sizing:content-box;"></td>
     <td style="width:25.959%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.65pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="4" style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SELECTED BALANCE SHEET DATA</font></p></td>
    </tr>
    <tr style="height:12.65pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="4" style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</font></p></td>
    </tr>
    <tr style="height:12.65pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="4" style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
    </tr>
    <tr style="height:12.65pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12.65pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30,</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    </tr>
    <tr style="height:12.65pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                            943,103</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                         1,118,302</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Working capital</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                            867,794</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                         1,078,428</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                            979,910</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                         1,141,752</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                            134,511</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                              71,960</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
    <tr style="height:12.25pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                            845,399</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0in;padding-right:0.08in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;$                         1,069,792</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img8926856_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8926856_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !P <,# 2(  A$! Q$!_\0
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M\*R*JM<:;<_M2_%/P^J6[_+ &OOA%\)-9A-W=KMEN$LO%/Q7M=*2WU"S9O\
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M[_@NZ/YYZ@NO^/:X_P"N$W_HMJ_H?^R_\&PG_07_ ."GG_@-X5_^5-13VO\
MP; ^3-YNK_\ !3T1>5)YA6V\+[A'L.\KLT@OG;G&T%L_=&<5JL[U7_"/GVZ_
MYEDO+_I[Z_=YB]E_T]H?^#5Y>7G^'FC^_3]B#_DRW]D+_LU[X ?^JH\)5\+?
MMS_\EPB_[$?P[_Z7:[7Z-_LR_P#""?\ #-W[/O\ PJW^WO\ A6/_  I#X4?\
M*Y_X2KR?^$H_X03_ (0/0/\ A$/^$D^S_N/[>_X1_P#L_P#MCR/W/]H_:/+^
M3;7RU^U#_P ,X?\ "SE_X6K_ ,+/_P"$I_X1G2-@\)?V9_9/]E?:-2^Q_P#'
MQ^^^U>=]L\[?V$>WY<9_'LCK^RSFO5]C7J7CBOW=*GSU5S5$]875N7:6NCT/
MD?%'!?7^%(8?ZW@<%_PH8*?M\?B/JV']V%9<GM>2?ORO[D>7WK/56/S#HKZR
M_P",)_\ JNW_ )1J/^,)_P#JNW_E&K[G^TO^H#,O_"7_ .Z'\X?ZL_\ 51<+
M?^'?T_ZA_/\ +OI\IVUS<V5Q!>6=Q<6=Y:RK/:W=I-+;75M.GW)K>XA9)H)D
M)RDL3I(AY5@:^Y_@]^V[XJ\,&WT7XIP7/C+0T6.&+Q!:);Q^*K!%*H&NT)M[
M/Q!$B??>9K/5#AII;W49F$3<)_QA/_U7;_RC4$_L3 $D_'8 <DG^QL >IKCQ
MD\)CZ?L\5E685%]F?U6U2F^].HJG-'5*Z3Y9;236A[61TLXX=Q/UK*.+^&\+
M)M.K26<<^&Q"5O=Q&'GAW2K*S:C*4>>%[TYPD^9?K;X(^(/@WXCZ.FN^"O$&
MGZ]I[;5F-K(4N[&5PQ%MJFG3K%?Z7=D*S"VU"VMYFCQ*B-$Z.W8U^>_P)^%'
MPCU>^3QK\,3^T#X-MK2!YH_&&KWNAZ'HE];JN]H$6\@N4U^P<;FE TW4-)5H
MC]JDC=4S^@$$L1+6HNUN;FT2%+G<\!N59X]T<ES% L:0O<*IE 6&&-LL8HU0
M #\[S##4,-7E3H5*LXK>%>FH5J6WNU.24H-ZK5<KOO"-U?\ IWAK-,PS7+:6
M)S+#X*E6FER5\NQ4\1@<9&S?ML/[:G2K4XMJ34'[>%E>.(J-24;%%%%<)]$%
M%<=\1/%O_" _#_QSXZ_LR;6_^$+\'>)O%O\ 8UM.EM<:O_PCFBWNL?V9;W,D
M<R6\U_\ 8_LL4[Q2I%)*LC1N%*G^5'X=_P#!W/\ LO>*O%7@S3?&7[*_QM^'
M?@SQ'K&B6?B#QW<^+/ WB:#P5HFK7$$5WXGU'0-&<:IJUAH5O.=0U.RT4W>J
M2V5O<?V7::A>""TN/3P&3YEF<*]3 82>)AAW!5G"5-.#FIR@E&<XSFY*G.RA
M&3;5MVD\YU:=-I3ERN5[73ULTGJDUI=7OWOL?UOT5B^&_$>@>,?#N@^+O"FM
M:7XD\+>*=%TOQ'X:\1:'?6VIZ+K^@:Y8P:GHVM:1J5G)-::AI>J:==6U]I]]
M:RRVUW:3PW$$CQ2*QVJ\UIIM---.S3T::W371HT"BBBD 45^#/[ '_!=[X9_
MM]?MA^+_ -C[PS^SQ\1OAOXB\(^&_BGXDG\;>)/%OA/6= OX/A7XOT'P?J%O
M:V&D*NJ1R:Q<Z]!?Z:]PD8BLX)5O5@NBD!_>:NO&X#%Y=65#&T70JRIQJJ#E
M"=Z<[\LKTY3C9\KTO?35$0G"HN:$E)7M=7W[:V[H****Y"PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **_S3/\ @KC^WW^W)\,/^"FO[:GP\^&_[7W[
M1W@/P'X2^+UMIGA;P;X2^+OC/0O#7AW3IOA_X)U*6QT;2+#58;.PM7U"_O;Q
MH+>)(_M%U,X4;\5_8-_P;X?%SXI_'#_@EQ\&?B+\9OB+XS^*OC_5/'GQ[L=3
M\:>/_$&H^*/$^H66B?&OQSI&C6EYK.JS7%[<0:5I5G::;8QR2L+>SMH85^5.
M?I\SX7Q.693A,WJXG#U:6+>#4:--5%4A]<PL\5#F<HJ#Y(0<)V?Q-<MXZG/3
MQ$:E65)1DG%3=VU9\DU!^>K=UY+4_:VBBBOF#H"BBB@ HHHH **** "BBB@
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MQCX3\.VTR7U[I][!#'9S7$^ZUF9HEC0O2?M0?\%(?V(_V+_&'AWP#^U#\?\
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M*UTWC9BWC;QHS'+-XP\4L3P,DZ]J!)P.!R>W%<S7],0^"/\ AC^2/ "BBBJ
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M[""UTO\ IA_X.[?CYKUI8?L:?LNZ7<O#X:\17?Q.^/7C>!)GC^VZKX.C\.>
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MAU+Q-XBO@JR-%;'4-3GG>UTZUWLMAI-B+72M.B/D:?96L $8XFH+K_CVN/\
MKA-_Z+:N_ Y9@\!*4Z%.4J]5KV^,Q$Y8C&XAJVM?$U+U)[)\D7&E%_!3@M"9
M5)3MS/1;1BN6$?\ #%:+\WU;/]@[]B#_ ),M_9"_[->^ '_JJ/"5?"W[<_\
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M# FI6?CSQG96DFF^"+R2'>&'PP\&V_AWP!)Y<\UK=:OH6LZW;^4=9EC7F/\
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M%M7^O-^V5^P%^RC^WOX#/@3]ICX4:+XT^Q6UW%X4\;6BC1/B5X NKN-U;4/
M_CFP1-;T.99'$\VG^=<Z#JCHL.N:/JEH9+9_X6O^"CG_  ;8_M9?LGVOB7XC
M?LQW&K?M=_ RSM[V_?3=!T)+7]H+P3IL4!D:+7O FD^;8_$FWM8UD>3Q#\.8
M+35;IB=_PWTJVA:\E_6<DXTRW,Y0HXIQR[%MQ2A6G?#UI-I6I8AJ,8-O54Z_
MLWJH0G5EOYU;"U*=Y1]^&]TO>2\X[OUC?9MI']YO[$'_ "9;^R%_V:]\ /\
MU5'A*OCW]K+PCK/CW]ISPYX-T"(2ZMXA\,>&+"V+*[Q6Z&]U^:\U"Y$8+BST
MRQAN=1O60%DM+69E!( K[&_8EAEM_P!C+]D>WN(I()X/V8O@)#-#,C12PRQ?
M"KPHDD4L;A7CDC=61T=0R,"K $$5O>-/A]K5EXJ\8?%'PA86VM?$76O"&E>
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nuvl-20251030.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-10-29T10:55:13.5054+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.nuvalent.com/20251030" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nuvl="http://www.nuvalent.com/20251030" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="nuvl-20251030.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 30,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NUVALENT, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001861560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5112298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Broadway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">357-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NUVL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nuvl-20251030.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="nuvl-20251030.htm">nuvl-20251030.htm</File>
    <File>nuvl-20251030.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nuvl-20251030.htm": {
   "nsprefix": "nuvl",
   "nsuri": "http://www.nuvalent.com/20251030",
   "dts": {
    "inline": {
     "local": [
      "nuvl-20251030.htm"
     ]
    },
    "schema": {
     "local": [
      "nuvl-20251030.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251030.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nuvl-20251030.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.nuvalent.com/20251030/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-25-257347-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-257347-xbrl.zip
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M1DW5=K1F+C5SZ6GGDBY4PPA,BWHZS@N3:=3CCDX#AVFAJ>IJN*JY=,Y&W2K
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M@B1_1P-@)"X>&Y"Y\K71"F#8"3S;$"K5#6%14V4>]8.048/;OFX*FVG.TLL
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MCUK,\T.&FT.7WY1RD@G4)/ D-WG,"*Y&LN,PQ$/!&KAXC7 !(TZ#J2&_5[O
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M6OH-LS*$IO02YD &^("1-@4&4?58'.(J#0N2:[\J <;0#!/((XL#+.FE&1"
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MG_C?(2#6O@[DMW>VSR >S=B59KXS?T>C*#RW4A4X>NTR4IYBT.^ #PX(!>$
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M]YXUK(I,%AXFOMR=_\._QCVX?*$GOK0_O!#[:O_@2O!?"US^#U!+ P04
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M0W+\^[^/7H->"B8#J$TN]8&ZZ)21,1?1C,8!3"5-\'OB@@I&PSD(/#>5P%V
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M%2G(4NDXL+0O2*=+YC$HZ\ 334"2ARKO&J[<.?_M_>N2__@6?VTY* +3KLD
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M934YSY1/%MC_#_E%.?.:5>L4+Z:5<[:<18]/5\21%<&4*60IR7Y%"B'YF-V
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MG )V1><R1Y>RH0;81B]!E.#CV63BI]=$M0!08ZD)JW"*"O.IM,L )@_KAZ$
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M 0 /              "  ?D<  !N=79L+65X.3E?,2YH=&U02P4&      ,
, P"[    L#X

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>nuvl-20251030_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nuvl-20251030.xsd" xlink:type="simple"/>
    <context id="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001861560</identifier>
        </entity>
        <period>
            <startDate>2025-10-30</startDate>
            <endDate>2025-10-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_89f59280-d8f3-447d-aff8-b9d365882a8c">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_7054fb88-614d-46cc-915f-65eee7d64132">0001861560</dei:EntityCentralIndexKey>
    <dei:DocumentPeriodEndDate
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_88a899f4-0f6b-41ac-8118-7367fb65b1b8">2025-10-30</dei:DocumentPeriodEndDate>
    <dei:DocumentType
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_50d5accb-cfa2-4abd-b085-2bc11da5c74d">8-K</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_5453cb9d-6e87-48a3-8518-38b7f9807562">NUVALENT, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_e4cd871f-ca29-4943-bbbd-ee458fd8514f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_ce06a6cc-93db-44c8-8da6-c3316d2c236e">001-40671</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_2e033c45-9294-44a1-9d72-c7a1f4020f6e">81-5112298</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_39e25be9-cbee-4363-99e3-7b8c1929f463">One Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_76eb890e-a6fe-4b05-b086-48ab1fa2e4a7">14th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_f850d876-dbc2-44a5-8af7-e02374202274">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_2371a8b9-05f7-4687-9021-fb7ffd7f008e">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_f3f6fcc3-f966-4219-a45f-fd0045f6e4a4">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_27c963e0-23e5-40a9-bcfa-3d6b24e6a173">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_e9710ec7-d4f6-4872-8b54-3684d7a14ad1">357-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_3ea54912-5906-4e82-bfb7-5ec75f26b856">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_5a64d1a3-eaa6-464c-bb0c-3b9a04198e27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_721632af-2e9b-450f-97a9-5a9bfab7f94f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_a28366c5-0772-4de5-b30f-1f95b89c9c0e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_8761d797-43d2-4f0b-b077-1623f7adc249">Class A Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_1e7ba9cc-8448-4529-a456-14672eb67a52">NUVL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_d9fb62fd-7516-45c0-bd3c-9b8073fa581c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_4382f27a-5c94-41a8-b7f8-ab0fb59af00e"
      id="F_b50ef5bc-8486-44b2-8cd5-38fbbde9086f">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
